T1	Participants 35 87	ong-term exogenous subclinical hyperthyroid patients
T2	Participants 687 814	25 patients with a history of differentiated thyroid carcinoma on long-term TSH-suppressive levothyroxine (l-T(4)) substitution
T3	Participants 930 963	dditionally 40 euthyroid controls
